Last month we told you about a Canadian study that will help doctors understand how well people living with myeloma respond to COVID-19 vaccines, as well as how to best continue protecting them from infection. The “VIP” study is now open in Ottawa and Toronto, with plans to also open in Edmonton and Montreal. Go to the study website to learn more and to enroll: https://omc.ohri.ca/VIP/pages/About.aspx.